Cas Nuclease Market Report 2024

This Cas Nuclease market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The Cas nuclease market size has grown rapidly in recent years. It will grow from $2.75 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth during the historic period can be attributed to the rise of genome editing, increased funding for biotechnology research, heightened demand for personalized medicine, government support for genetic research, and the growing prevalence of genetic disorders.

The Cas nuclease market size is expected to see rapid growth in the next few years. It will grow to $6.56 billion in 2028 at a compound annual growth rate (CAGR) of 19%. The projected growth during the forecast period can be attributed to increasing investment in gene editing startups, rising demand for therapeutic genome editing, regulatory approvals for gene therapies, the development of Cas-based diagnostics, and growing interest in epigenome editing. Key trends expected in this period include the adoption of CRISPR for treating rare diseases, growth in agricultural gene editing, heightened interest in synthetic RNA-guided nucleases, advancements in CRISPR-based drug discovery, and a rise in ethical debates surrounding genome editing.

The increasing investment in biotechnology is projected to drive the growth of the Cas nuclease market in the coming years. This surge in investment is propelled by significant breakthroughs in scientific research, a rising demand for advanced medical treatments, the expanding applications of biotechnology across various industries, and the substantial economic potential associated with innovative technologies. Investment in biotechnology, particularly in Cas nucleases, accelerates advancements in gene-editing technologies applicable to medical, agricultural, and research fields. For example, in August 2024, data released by the UK Bioindustry Association (BIA), a trade association for the innovative life sciences and biotech sectors, indicated that the UK's life sciences and biotech sector raised $2.61 billion in the first half of 2024, surpassing the total of $2.38 billion raised throughout 2023. Consequently, the growing investment in biotechnology is driving the Cas nuclease market forward.

Key companies within the Cas nuclease market are concentrating on developing advanced technological solutions, such as CRISPR-based gene editing therapy, to maintain their competitive edge. CRISPR-based gene editing therapy employs the CRISPR-Cas9 system to precisely modify DNA sequences in living organisms, enabling the treatment of genetic disorders by correcting mutations at the molecular level. For instance, in November 2023, Vertex Pharmaceuticals Incorporated, a U.S.-based biotechnology firm, in collaboration with CRISPR Therapeutics, a Switzerland-based gene editing company, announced the authorization of CASGEVY (exagamglogene autotemcel) by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). This approval represents a significant milestone, as it is the first-ever gene therapy utilizing CRISPR/Cas9 technology approved for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older.

In February 2024, Ginkgo Bioworks, a U.S.-based biotechnology company, acquired Proof Diagnostics Inc. for an undisclosed sum. This acquisition aims to bolster Ginkgo's gene editing capabilities by integrating Proof's innovative Omega ribonucleic acid (RNA) programmable nuclease libraries, providing a new, versatile tool for advancing genomic medicines and therapeutics. Proof Diagnostics Inc. is a U.S.-based life sciences company specializing in a cutting-edge, CRISPR-based platform that includes Omega nuclease and CRISPR Cas technologies.

Major companies operating in the cas nuclease market are Thermo Fisher Scientific Inc., AstraZeneca PLC, Merck KGaA, Vertex Pharmaceuticals, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Promega Corporation, GenScript Biotech Corporation, CRISPR Therapeutics AG, Integrated DNA Technologies Inc., Takara Bio Inc., New England Biolabs Inc., Horizon Discovery Group plc, OriGene Technologies Inc., Applied Biological Materials Inc. (ABM), Synthego Corporation, Novoprotein Scientific Inc., genOway, Precision BioSciences, Editas Medicine, Creative Biolabs, Cellectis, Caribou Biosciences, Addgene.

North America was the largest region in the Cas nuclease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cas nuclease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cas nuclease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cas nuclease is an enzyme derived from CRISPR systems, capable of being programmed to target and cleave specific DNA sequences, thus enabling precise genetic modifications. It plays a crucial role in genome editing for correcting genetic mutations, creating genetically modified organisms, and developing targeted therapies for various diseases.

The primary types of Cas nucleases include Cas9, Cas12, Cas13, and others. Cas9 is a CRISPR-associated endonuclease that introduces double-strand breaks in DNA at specified locations, guided by a complementary RNA sequence, to facilitate accurate gene editing and manipulation. These nucleases can be delivered through various methods, including viral vectors, lipid nanoparticles, electroporation, microinjection, and transposons. Distribution channels for Cas nucleases encompass direct sales and distributors. Their applications range from gene editing and cell line construction to the development of animal models, bioagriculture, gene therapy, and more. Key end users of Cas nucleases include academic and government research institutions, biotechnology and pharmaceutical companies, contract research organizations (CROs), and agricultural biotechnology firms, among others.

The Cas nuclease market research report is one of a series of new reports that provides Cas nuclease market statistics, including Cas nuclease industry global market size, regional shares, competitors with a Cas nuclease market share, detailed Cas nuclease market segments, market trends and opportunities, and any further data you may need to thrive in the Cas nuclease industry. This Cas nuclease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Cas nuclease market consists of sales of CRISPR-Cas9 kits, Cas12a systems, Cas nuclease proteins, and gene-editing solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.